I would like to invite you to our next
webinar “PwC webinar – “Sourcing and manufacturing without side
effects!” which will be held on 31 March 2020 from 3:00 pm to 4:00 pm and
on 1 April 2020 from 9.00 am to 10.00 am.
We will also include some ITX Updates
related on COVID-19.
Continue reading PwC webinar – “Sourcing and manufacturing without side effects!” / COVID-19 ITX Update
the economic impact is unknown scenario planning is key
The impact and effects of COVID-19 are
being felt by businesses globally, and particularly in China where necessary
radical measures to contain the outbreak are impacting day to day life.
Continue reading Succeeding in Uncertainty: Responding to COVID-19
Medical devices suppliers conducting agreements for allowing hospitals to use free of charge their equipment might face both VAT and corporate tax adverse implications.
Continue reading Cutting edge tax implications for medical devices suppliers in Europe
gilt als Kernwert des Wirtschaftsstandorts Schweiz – und der MedTech-Branche.
Das Volks-Ja zur Steuerreform hat der innovativen Tätigkeit von Unternehmen wie
Ihrem eine neue Bedeutung verliehen. Auch andere nationale und internationale
Neuerungen der indirekten Steuern und Zölle sowie neue regulatorische
Rahmenbedingungen wirken sich 2020 auf die aktuelle und zukünftige Situation Ihres
Wie daraus ein echter
Mehrwert generiert werden kann, möchten wir gerne an unserem speziell der
MedTech Branche gewidmeten Event mit Ihnen diskutieren.
Continue reading Event: “Tax Engineering” für MedTech – 19. März 2020, PwC Luzern
1. The background in a nutshell
- Until 25th May 2020
all Medtech products that are admitted in Switzerland for the sale can be
distributed also in the EU.
- However, currently a
new treaty is negotiated by Switzerland and the EU Joint Committee in that
- In case the treaty is
not going to be concluded between Switzerland and the EU, all Medtech
companies based in Switzerland are considered as not being anymore part of the
EU. Indeed this treaty hangs by a
the latest developments of the Swiss-EU negotiations concerning the
Institutional Agreement and the Mutual Recognition Agreement (MRA),
Swiss Medtech companies should be preparing for the case in which MRA would
no longer apply to the medical devices after 26th May 2020.
Continue reading Swiss Medtech companies – action required for the sale of products in the EU as per May 2020 – Is your business ready for the upcoming changes?
On November 15, in Lugano we have been honored to host the annual Tax Forum, which represents for PwC the main tax event in the Ticino area. This year we had the pleasure to host, as guest speaker, the Federal Councilor Ignazio Cassis, head of the Federal Department of Foreign Affairs.
Continue reading Pharma & Life Sciences – The future is now: from digitalization in tax to AVIS28
I would like to invite you to our next webinar “Pharma & VAT Quick Fixes – Exploring the Right Formula which will be held on 8 November 2019 from 9:00am to 10:00am and from 3.00pm to 4.00pm.
Continue reading Webinar: Pharma & VAT Quick Fixes – Exploring the Right Formula
Why should you as a pharma & life
sciences company register to the event?
- you will gathering insights on
relevant topics of the Swiss VAT authorities – directly from the competent
officer of the Federal Tax Administration (FTA)
Continue reading Last chance to register for our PwC event “4. Schweizer MWST-Tagung” in our beautiful capital Bern
- you strive to be prepared as
per 1 January 2020 regarding the EU VAT Quick Fixes and its implications e.g.
for pharma & life sciences companies
I hope you had a relaxing summer time.
Do you face troubles in order to be up to
date with all the required legislation changes in various countries in the
Regulatory Pharma & Life Sciences field AND combine it with your supply
chain and tax strategy?
I am happy to inform you that we have recently
launched our Pharma & Life Sciences Regulatory Radar, to strive to assist
you in that regard.
Continue reading Cutting Edge Digital Solution – Pharma & Life Sciences Regulatory Radar
Recently you received a lot information related to Brexit. The key question in that regard: what is the next most favorable step for your Pharma and Life Sciences business? The center of the discussion should still be the handling of your supply chain.
Continue reading Brexit? What next for Pharma und Life Sciences businesses?
Please find hereinafter some inputs in that regard from an UK, Ireland and Swiss perspective for your convenience: